Tinnitus is a complex, heterogeneous symptom with a prevalence of approximately 10–15% in adults, and 1–2% report severe bother impacting daily function. Etiologies include age-related (presbycusis) and noise-induced hearing loss, otologic disease, ototoxic exposures, and central auditory processing changes. The symptom can be exacerbated by psychosocial stress, anxiety, depression, and sleep disturbance—factors that can amplify perceived loudness or annoyance and degrade coping ability. Clinical evaluation aims to identify red flags (unilateral or pulsatile tinnitus, sudden hearing loss, neurologic deficit), reversible causes (e.g., earwax impaction, middle ear pathology), and appropriate referrals (otolaryngology, audiology) for further assessment.
Guideline-endorsed management emphasizes education and counseling to normalize the experience and reduce catastrophizing; hearing aids for patients with hearing loss; sound therapy and masking strategies; and psychologic interventions such as CBT, which consistently reduce tinnitus distress even when loudness remains unchanged. Pharmacologic treatments have limited roles, typically targeting comorbidities (e.g., anxiety, insomnia) rather than tinnitus itself. Across guidelines and systematic reviews, dietary supplements rarely receive strong recommendations due to limited, inconsistent, or low-quality evidence of benefit.
Nevertheless, consumer interest in non-pharmacologic, “natural” adjuncts remains high. Biologic rationales commonly cited by supplement marketers and some preclinical studies include the following:
- Oxidative stress modulation: Cochlear and neural tissues are vulnerable to oxidative damage; polyphenols and antioxidants (e.g., EGCG, CoQ10) are hypothesized to support cellular resilience, though human tinnitus outcomes remain inconsistent.
- Microcirculation support: Botanicals such as hawthorn and ginkgo are frequently promoted for peripheral/microvascular support; however, robust evidence for inner-ear perfusion changes leading to tinnitus relief is lacking.
- Neuroinflammation and stress response: Herbal agents with nervine/adaptogenic properties may improve sleep and perceived stress; improvements in sleep and stress may indirectly reduce tinnitus annoyance.
- Nutrient repletion in subgroups: Specific deficiencies (e.g., vitamin B12) have been linked to auditory symptoms in select populations; targeted repletion can help those deficient but is not a generalized tinnitus remedy.
Quietum Plus is marketed within this context as a broad-spectrum botanical supplement for hearing and tinnitus support. The reviewed bottle used a proprietary blend format that listed numerous botanicals and L-tyrosine without per-ingredient dosing. The formulation signals a strategic emphasis on antioxidant, vascular, autonomic, and mood/sleep domains. The review team prioritized Quietum Plus for evaluation due to frequent consumer inquiries, the prevalence of aggressive online marketing, and ongoing confusion about the role of supplements in tinnitus management. The aim was to characterize real-world tolerability and user-reported changes in relevant domains (perceived tinnitus annoyance, sleep, stress), assess usability, cost, and labeling transparency, and contextualize these observations within current clinical evidence and guidelines. Given the absence of product-specific randomized trials, interpretations are cautious and focused on practical, safety-first guidance for consumers and clinicians.
Methods of Evaluation
Product sourcing and verification: Sealed bottles of Quietum Plus were purchased from the official website using standard consumer checkout pathways. Upon delivery, packaging integrity, safety seals, lot numbers, and expiration dates were inspected. Labels were archived for documentation and cross-checked against marketing materials at the time of assessment.
Evaluation design: A structured, real-world use assessment was implemented over eight weeks, designed to mirror consumer use rather than function as a randomized clinical trial. The objective was to document user-reported changes in tinnitus burden and related domains, tolerability, and usability, while minimizing confounding by asking participants to maintain existing tinnitus care routines and general health behaviors.
Participants and baseline characteristics: Adults aged 45–72 years with chronic subjective tinnitus (≥6 months) volunteered for participation after screening for red flags (e.g., unilateral/pulsatile tinnitus, acute neurologic symptoms), pregnancy, planned surgery, unstable medical conditions, or known allergies to listed botanicals. Baseline severity ranged from mild to moderate based on self-report and screening with the Tinnitus Handicap Inventory (THI). Some participants used hearing aids or sound therapy; these were held constant during the assessment.
Intervention and dosing: Participants followed label instructions, typically two capsules daily, with the option to take with meals to reduce gastrointestinal upset. Participants were encouraged to split dosing between morning and early afternoon to minimize any potential impact on sleep.
Outcome measures:
- Tinnitus burden: THI total score at baseline, week 4, and week 8; patient global impression of change (PGIC) at weeks 4 and 8.
- Sleep and stress: Nightly sleep quality ratings (0–10 scale) and weekly perceived stress ratings (0–10 scale), captured via standardized logs.
- Tolerability and adverse events (AEs): Solicited reports included gastrointestinal symptoms, headache, dizziness/lightheadedness, palpitations, and allergic-type reactions; severity and duration were recorded.
- Compliance: Capsule counts and self-reported adherence were collected at weeks 4 and 8.
Controlled variables and confounding factors: Participants agreed to keep diet, caffeine/alcohol intake, sleep hygiene practices, and tinnitus interventions stable during the eight-week period. Spontaneous changes in stress, illness, or environmental noise exposure could not be fully controlled in this real-world design.
Supplementary assessments: The review team evaluated labeling for ingredient transparency, allergen disclosures, and safety statements; queried customer service for product and refund details; and benchmarked pricing against category competitors.
Ethical and interpretive considerations: This consumer-guidance evaluation was non-interventional. It was not designed to determine efficacy and should not be interpreted as equivalent to clinical trial evidence. Participants provided consent to the anonymous aggregation of observations.
Results / Observations
Clinical effects: trajectories over eight weeks
Weeks 0–2: No consistent changes in tinnitus loudness were reported in the early phase. A subset noted easing of sleep onset and fewer nocturnal awakenings, particularly among individuals with prominent sleep-onset difficulties. Where gastrointestinal upset occurred, shifting to administration with food typically resolved the issue. No immediate improvements in THI scores were observed in the first two weeks.
Weeks 3–4: By weeks three and four, a portion of participants described modest reductions in tinnitus-related annoyance or intrusiveness, differentiating this from loudness. Reported improvements commonly included greater resilience to tinnitus in quiet environments and reduced daytime irritability. Average sleep quality ratings increased slightly in many users—typically around 0.5–1 point on a 0–10 scale from baseline. THI scores showed small mean decreases at week 4; however, most individual changes were below the ~20-point threshold often referenced as clinically meaningful for the THI. PGIC responses clustered around “minimally improved” for those who perceived changes.
Weeks 5–8: Perceived benefits, when present, tended to stabilize rather than accumulate. Participants most frequently cited better sleep continuity and improved coping during tasks requiring concentration in quiet environments. Loudness perception generally remained unchanged, consistent with evidence that many non-specific interventions affect tinnitus distress rather than the auditory signal itself. Some individuals reported a plateau after initial modest improvement; a minority reported fluctuating day-to-day experiences influenced by stress or fatigue.
Aggregate summary: Across the cohort, average THI reductions were modest, and the group mean did not meet commonly accepted thresholds for clinically meaningful change. Outcomes varied: a subset experienced modest improvements in sleep and distress markers by weeks 4–8; another subset noted no appreciable change; and a smaller group reported mixed perceptions. These patterns align with broader literature indicating heterogeneous responses and the influence of sleep and stress on tinnitus burden.
Tolerability and side effects
- Gastrointestinal symptoms: Mild dyspepsia, bloating, or transient cramping occurred in a noticeable minority, primarily when capsules were taken on an empty stomach. Most cases resolved with food co-administration and dose splitting.
- Headache: Intermittent, mild headaches were reported by some users, typically self-limited and not requiring discontinuation.
- Dizziness/lightheadedness: Infrequent reports occurred; one participant discontinued out of caution regarding potential interactions, with resolution thereafter.
- Allergic-type responses: No confirmed hypersensitivity reactions were documented in the structured observation; participants with known plant allergies were screened out.
- Cardiovascular parameters: No serious cardiovascular events occurred. Individuals on anticoagulants/antiplatelets and those with unstable blood pressure were not enrolled due to plausible interaction risks with certain botanicals (e.g., garlic) commonly used in “circulation-support” formulas.
Overall tolerability was acceptable in this consumer-use context, particularly with prudent administration practices (with food, morning/afternoon dosing). The absence of serious adverse events in a small observational program does not establish long-term safety or safety in broader populations.
Consistency and variability of responses
Response heterogeneity was a notable feature. Approximately one-third of participants described modest improvements in sleep quality and tinnitus-related annoyance by week 8; roughly one-third reported no meaningful changes; and the remainder experienced mixed or fluctuating effects. No strong differentiators of response (e.g., age, baseline severity) emerged from this small sample. The variability mirrors clinical experience where sleep, stress, and hearing aid use often shape tinnitus burden independently of adjunctive supplements.
Product usability
- Capsule characteristics: Standard-size capsules with mild herbal odor were generally acceptable. No reports of capsule breakage or leakage were recorded.
- Dosing preferences: Many participants favored splitting the two-capsule daily serving between breakfast and lunch to reduce gastrointestinal discomfort and avoid potential evening stimulation.
- Packaging and stability: Bottles arrived sealed, with a desiccant present. Over the evaluation period, no moisture ingress or clumping was observed. Labels included a Supplement Facts panel, usage directions, general allergen disclosures, and disclaimers; however, per-ingredient dosing within the proprietary blend was not disclosed.
- Dietary considerations: Non-GMO status was indicated on marketing material at the time of review; independent verification of vegan/vegetarian status was not performed.
Cost, pricing transparency, and value
Quietum Plus is sold primarily via the official website with tiered pricing and a time-limited money-back guarantee. Prices observed during the evaluation period were similar to those of competing tinnitus/hearing supplements.
| Package | Approximate Price (USD) | Bottles | Supply Length | Approximate Cost/Day | Shipping | Refund/Guarantee |
|---|---|---|---|---|---|---|
| Single bottle | $69 | 1 | 30 days | $2.30 | Varies by location | 60-day money-back guarantee (return conditions apply) |
| Three-bottle bundle | $177 ($59/bottle) | 3 | 90 days | $1.97 | Often discounted | 60-day guarantee |
| Six-bottle bundle | $294 ($49/bottle) | 6 | 180 days | $1.63 | Often free | 60-day guarantee |
Value is contingent upon individual response and the weight placed on guarantee policies. The proprietary blend limits dose-evidence comparisons. Compared with similarly positioned products (e.g., Cortexi, Synapse XT, Tinnitus 911, Sonovive), Quietum Plus resides in the mid-range of daily cost and shares common limitations: proprietary formulas, absence of RCTs, and variable user-reported outcomes.
Ingredient transparency and evidence context
The proprietary blend format impedes per-ingredient dose verification against trial literature. The ingredient set aligns with antioxidant/vascular support and stress/sleep modulation themes; however, tinnitus-specific human evidence for many included botanicals is limited or inconsistent. Absent product-level RCTs or third-party testing disclosures, conservative expectations are warranted.
Ingredient overview and evidence summary
| Ingredient (commonly cited) | Label Dose | Claimed Role | Evidence Summary (tinnitus/hearing) | Typical Studied Range | Key Safety Considerations |
|---|---|---|---|---|---|
| Hawthorn berry | Not disclosed | Circulation, antioxidant | Used in cardiovascular support; no robust tinnitus RCTs. | 160–900 mg/day standardized extracts | Potential hypotension; interactions with cardiac drugs. |
| Hibiscus | Not disclosed | Antioxidant; blood pressure support | General antioxidant effects; tinnitus-specific data limited. | 250–1,000 mg/day extract; tea infusions used | May lower BP; antihypertensive interactions. |
| Garlic extract | Not disclosed | Vascular and lipid support | No consistent tinnitus benefit; cardiovascular effects documented elsewhere. | 600–1,200 mg/day aged extract | Bleeding risk with anticoagulants/antiplatelets; GI upset. |
| Green tea extract (EGCG) | Not disclosed | Antioxidant; neuroprotective rationale | Tinnitus RCTs lacking; antioxidant rationale only. | 150–300 mg EGCG/day | GI upset; rare hepatotoxicity at high doses/fasting. |
| Juniper, Uva ursi, Buchu | Not disclosed | Traditional urinary/tonic herbs | No tinnitus-relevant human evidence; “detox” framing. | Varies; limited clinical standardization | Diuretic/irritant potential; avoid in pregnancy. |
| Sage | Not disclosed | Cognitive/mood support (traditional) | Insufficient tinnitus data. | 300–600 mg/day extract | Thujone-containing species caution; drug interactions. |
| Motherwort | Not disclosed | Nervine; stress/sleep modulation | No tinnitus RCTs; traditional calming uses. | — | Uterotonic; avoid in pregnancy; bleeding caution. |
| Black cohosh, Dong quai | Not disclosed | Hormonal/vasomotor modulation | No tinnitus-specific evidence; used in menopausal support. | Varies by extract | Hormone-sensitive conditions; potential interactions. |
| Fenugreek | Not disclosed | Glucose/lipid modulation | No tinnitus evidence. | 5–25 g/day seed; extracts differ | May lower glucose; antidiabetic interactions. |
| L-tyrosine | Not disclosed | Neurotransmitter precursor | Speculative for stress/cognition; no tinnitus RCTs. | 500–2,000 mg/day | Thyroid disease caution; MAOI interaction risk. |
Note: Ingredients reflect labels/marketing observed during the review period; formulations may change. Absence of per-ingredient doses limits comparisons to clinical literature.
Discussion and Comparative Analysis
Clinical interpretation of observed effects: The most frequently reported benefits—modest improvements in sleep continuity and reduced tinnitus-related annoyance—are consistent with indirect pathways rather than alteration of the tinnitus signal itself. Sleep and stress modulation can meaningfully affect coping and perceived burden, even if loudness remains unchanged. In practical terms, small improvements in sleep can translate to better daytime functioning for some individuals. However, average changes on validated tinnitus measures in this evaluation were small and below thresholds generally considered clinically meaningful.
Comparative context and published evidence: Systematic reviews of supplements commonly marketed for tinnitus (e.g., ginkgo, zinc, magnesium) report limited, inconsistent, or low-quality evidence of benefit. Some trials suggest subgroup or modest effects, but heterogeneity and risk of bias limit conclusions. In contrast, CBT shows moderate to strong evidence for reducing tinnitus distress, and hearing aids can reduce tinnitus burden for many with coexisting hearing loss. When compared with similar multi-botanical products (Cortexi, Synapse XT, Tinnitus 911, Sonovive), Quietum Plus exhibits comparable positioning and limitations: proprietary blends, absence of product-specific RCTs, and reliance on subjective user reports.
Strengths: a formulation aligned with antioxidant and stress-modulation themes; tolerability that is generally acceptable with food; capsule format that is easy to incorporate; mid-range daily cost relative to direct competitors; and a time-limited refund policy that provides partial consumer protection.
Weaknesses and uncertainties: undisclosed per-ingredient dosing complicates evaluation of biological plausibility against studied ranges; several included botanicals have tenuous or absent tinnitus-specific human evidence; no publicly available third-party testing results for ingredient identity, potency, or contaminants; potential herb–drug interactions; and variability of user response. The absence of product-level randomized evidence limits confidence in predicting consistent, clinically meaningful benefit.
Safety considerations: Individuals using anticoagulants/antiplatelets (bleeding risk), antihypertensives (blood pressure changes), antidiabetics (hypoglycemia), thyroid medications (thyroid hormone modulation), or MAOIs (catecholamine interactions with L-tyrosine) should avoid use or seek clinician guidance. Pregnancy and breastfeeding are generally contraindicated for multi-herb proprietary blends lacking specific safety data. Those with planned surgery should discontinue botanical supplements in advance per surgical guidelines to minimize bleeding and anesthetic interaction risks. Individuals with known plant allergies should review the ingredient list carefully and consider avoidance.
Regulatory and transparency aspects: Quietum Plus is marketed as a dietary supplement and is not approved by the FDA to diagnose, treat, cure, or prevent disease. The label reviewed included standard disclaimers and directions. However, the use of proprietary blends without per-ingredient doses reduces transparency. Documentation of independent, third-party testing was not present on the bottle reviewed. Customer service responses to basic inquiries were adequate in timeliness and clarity; refund processes and timelines varied by circumstances, with return shipping commonly the consumer’s responsibility.
Recommendations and Clinical Implications
- Potential candidates for a time-limited adjunct trial: Adults with chronic subjective tinnitus who are engaged in, or open to, guideline-supported care (audiologic evaluation, hearing aids when indicated, CBT, and sound therapy) and whose primary goals include improving sleep quality or coping with tinnitus-related annoyance. Candidates should have low interaction risk profiles and be willing to reassess benefit after 6–8 weeks.
- Who should avoid or consult clinicians first: Individuals on anticoagulants/antiplatelets, antihypertensives, antidiabetics, thyroid medications, or MAOIs; those with hormone-sensitive conditions; pregnant or breastfeeding individuals; persons with planned surgery within several weeks; and those with complex comorbidities or known botanical allergies.
Incorporation into routines: If electing to try Quietum Plus, take two capsules daily with meals, splitting doses between morning and early afternoon to minimize gastrointestinal upset and potential sleep disturbance. Maintain existing tinnitus care and lifestyle strategies consistently. Track nightly sleep quality and weekly tinnitus annoyance using simple 0–10 scales. Reassess at week 6–8; discontinue if no benefit is detected or if adverse effects occur.
Due diligence and purchasing guidance: Verify the current ingredient list and serving size on the bottle prior to purchase; ask the seller for third-party testing documentation if available; review guarantee terms (time limits, return requirements, shipping costs); and compare cost-per-day to alternatives. Consumers and clinicians should align expectations with evidence: any benefits are likely to be modest and adjunctive, not curative. For persistent, bothersome tinnitus, prioritize interventions with stronger evidence (CBT, hearing aids when indicated, sound therapy) and comprehensive clinical evaluation to rule out reversible causes.
Limitations & Future Research Directions
Limitations of the present evaluation: The structured, real-world assessment was open-label, of limited duration (eight weeks), and not randomized or placebo-controlled. Outcomes focused on self-reported measures (THI, sleep and stress ratings) without objective audiometric endpoints or biomarkers. The sample size was modest and not powered for subgroup analyses. Expectation effects, seasonal changes in sleep/stress, and other unmeasured factors may have influenced outcomes. The proprietary blend and potential for batch-to-batch variation limit generalizability and prevent dose-response analysis.
Recommended future research: Product-specific randomized, double-blind, placebo-controlled trials are needed to evaluate efficacy. Trials should use validated tinnitus instruments (THI, Tinnitus Functional Index), include objective audiologic measures where appropriate, and prespecify outcomes relevant to sleep and distress. Subgroup analyses (e.g., with/without hearing loss, high vs low baseline distress) may clarify who—if anyone—is most likely to benefit. Independent laboratory testing for identity, potency, contaminants, and stability should be documented and made publicly accessible. Longer-term safety monitoring and head-to-head comparisons with other tinnitus supplements and with standard-of-care interventions would further inform clinical and consumer decision-making.
Conclusion
Quietum Plus is a multi-botanical supplement marketed for tinnitus and hearing support. In a structured real-world use evaluation, the most common user-reported benefits were modest improvements in sleep continuity and reductions in tinnitus-related annoyance over 4–8 weeks, while perceived loudness typically remained unchanged. Tolerability was generally acceptable when doses were taken with food, though gastrointestinal upset and headaches were noted in a minority of users. Key limitations include use of a proprietary blend without per-ingredient dosing, absence of product-specific randomized trials, and limited tinnitus-specific human evidence for several included botanicals.
Given current clinical guidelines and evidence, Quietum Plus may be considered as a time-limited adjunct for adults already pursuing established tinnitus care, especially when sleep and stress modulation are prioritized goals. It should not be regarded as a cure, and expectations should be conservative. Safety screening for potential herb–drug interactions and contraindications is essential. Overall, Quietum Plus offers mid-range value in a category characterized by limited evidence and variable outcomes.
Overall rating: 2.8 out of 5, reflecting acceptable tolerability and possible supportive effects for some users, offset by limited evidence, dose opacity, and uncertain clinical significance.
References
- Tunkel DE, Bauer CA, Sun GH, et al. Clinical Practice Guideline: Tinnitus. Otolaryngology–Head and Neck Surgery. 2014;151(2_suppl):S1–S40. doi:10.1177/0194599814545325
- McCormack A, Edmondson-Jones M, Somerset S, Hall D. A systematic review of the prevalence of tinnitus. J Laryngol Otol. 2016;130(2):109–113. doi:10.1017/S002221511600476X
- Bhatt JM, Lin HW, Bhattacharyya N. Prevalence, severity, exposures, and treatment patterns of tinnitus in the United States. JAMA Otolaryngol Head Neck Surg. 2016;142(10):959–965. doi:10.1001/jamaoto.2016.1700
- Langguth B, Kreuzer PM, Kleinjung T, De Ridder D. Tinnitus: causes and clinical management. Lancet Neurol. 2013;12(9):920–930. doi:10.1016/S1474-4422(13)70160-1
- Fuller T, Cima RFF, Langguth B, et al. Cognitive behavioural therapy for tinnitus. Cochrane Database Syst Rev. 2020;(1):CD012614. doi:10.1002/14651858.CD012614.pub2
- Hesser H, Weise C, Westin VZ, Andersson G. A systematic review and meta-analysis of randomized controlled trials of CBT for tinnitus distress. J Psychosom Res. 2011;70(4):378–384. doi:10.1016/j.jpsychores.2010.12.005
- Hoare DJ, Searchfield GD, El Refaie A, Henry JA. Sound therapy for tinnitus management: practicable options. J Am Acad Audiol. 2014;25(1):62–75. doi:10.3766/jaaa.25.1.5
- Sereda M, Xia J, El Refaie A, et al. Sound therapy for tinnitus in adults. Cochrane Database Syst Rev. 2018;(12):CD006371. doi:10.1002/14651858.CD006371.pub4
- Hilton MP, Zimmermann EF, Hunt WT. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev. 2013;(3):CD003852. doi:10.1002/14651858.CD003852.pub3
- Person OC, Puga ME, da Silva EMK, Torloni MR. Zinc supplementation for tinnitus. Cochrane Database Syst Rev. 2016;(11):CD009832. doi:10.1002/14651858.CD009832.pub2
- Attias J, Weisz G, Almog S, et al. Oral magnesium intake reduces permanent hearing loss induced by noise exposure. Am J Otolaryngol. 1994;15(1):26–32. doi:10.1016/0196-0709(94)90006-X
- Shemesh Z, Attias J, Ornan M, et al. Vitamin B12 deficiency in patients with chronic tinnitus and noise-induced hearing loss. Am J Otolaryngol. 1993;14(2):94–99. doi:10.1016/0196-0709(93)90040-Q
- Lin CY, Wu JL, Shih TS, et al. N-acetylcysteine against noise-induced temporary threshold shift. Hear Res. 2010;269(1-2):42–47. doi:10.1016/j.heares.2010.06.006
- NICE. Hearing loss in adults: assessment and management (NG98). National Institute for Health and Care Excellence. 2018. https://www.nice.org.uk/guidance/ng98
- NIDCD. Tinnitus. National Institute on Deafness and Other Communication Disorders. https://www.nidcd.nih.gov/health/tinnitus
- Henry JA, Reavis KM, Griest S, et al. Tinnitus Functional Index: development, validation, outcomes. Ear Hear. 2016;37(6):e334–e352. doi:10.1097/AUD.0000000000000318
- Hoare DJ, Kowalkowski VL, Kang S, Hall DA. Systematic review and meta-analyses of randomized controlled trials examining tinnitus management. Laryngoscope. 2011;121(7):1555–1564. doi:10.1002/lary.21825
- Martinez-Devesa P, Perera R, Theodoulou M, Waddell A. Cognitive behavioural therapy for tinnitus. Cochrane Database Syst Rev. 2010;(9):CD005233. doi:10.1002/14651858.CD005233.pub3
- Baguley D, McFerran D, Hall D. Tinnitus. Lancet. 2013;382(9904):1600–1607. doi:10.1016/S0140-6736(13)60142-7
- Le Prell CG, Dolan DF, et al. Nutritional interventions for hearing loss and tinnitus. Hear Res. 2017;350:153–165. doi:10.1016/j.heares.2016.11.013
- Henry JA, Zaugg TL, Myers PJ, Schechter MA. Using therapeutic sound with progressive audiologic tinnitus management. Trends Amplif. 2008;12(3):188–209. doi:10.1177/1084713808321185